Recurrent Pseudomonas aeruginosa pneumonia in ventilated patients: relapse or reinfection?

Am J Respir Crit Care Med. 1998 Mar;157(3 Pt 1):912-6. doi: 10.1164/ajrccm.157.3.9703014.

Abstract

A prospective observational study was performed to determine whether recurrent episodes of pneumonia caused by Pseudomonas aeruginosa in ventilated patients were due to a relapse of the previous clone or to reinfection with a new one. Diagnosis was based on quantitative cultures of secretions obtained by bronchoscopy. Comparison of strains was made by chromosomal fingerprinting based on pulsed field gel electrophoresis (PFGE). Thirty-three (89.1%) of 37 patients survived the initial week after pneumonia diagnosis; six survivors (18.1%) had multiple episodes caused by the same species. Presence of adult respiratory distress syndrome (83.3% versus 22.2%, p = 0.02) was the only factor significantly associated with clinical recurrences. The 16 isolates from five patients (nine recurrences) were analyzed by PFGE. All new isolates from recurrent episodes, excepting one, were considered as relapses. These data suggest that most recurrent episodes of P. aeruginosa pneumonia in ventilated patients occur due to persistence of strains present in a prior infection.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Analysis of Variance
  • Anti-Bacterial Agents
  • Bronchoalveolar Lavage Fluid / microbiology
  • Bronchoscopy
  • Cause of Death
  • Chromosomes, Bacterial / genetics
  • Colony Count, Microbial
  • Cytodiagnosis / instrumentation
  • DNA Fingerprinting
  • DNA, Bacterial / genetics
  • Drug Therapy, Combination / therapeutic use
  • Electrophoresis, Gel, Pulsed-Field
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Pneumonia, Bacterial / drug therapy
  • Pneumonia, Bacterial / microbiology*
  • Prospective Studies
  • Pseudomonas Infections / drug therapy
  • Pseudomonas Infections / microbiology*
  • Pseudomonas aeruginosa / classification*
  • Pseudomonas aeruginosa / genetics
  • Recurrence
  • Respiration, Artificial / adverse effects*
  • Respiratory Distress Syndrome / microbiology
  • Survival Rate

Substances

  • Anti-Bacterial Agents
  • DNA, Bacterial